Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06112028
Other study ID # 07
Secondary ID
Status Not yet recruiting
Phase Phase 4
First received
Last updated
Start date October 2023
Est. completion date November 2026

Study information

Verified date October 2023
Source Qianfoshan Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Intrastent restenosis is a common complication after intracranial and extracranial arterial stenting and an important cause of recurrent ischemic stroke. Studies have shown that Tongxinluo capsule can protect the injured inner cells, reduce inflammation, inhibit the proliferation and migration of smooth muscle cells, inhibit the proliferation of plaque and nourish blood vessels, and resist arteriosclerosis. This study was a multicenter prospective randomized controlled clinical trial. Participants with intracranial and extracranial atherosclerotic stenosis who successfully underwent arterial stenting were included in the study, and were divided into Tongxinluo test group and control group. Clinical and related auxiliary examination data were collected at each follow-up point. To explore the effectiveness and potential mechanism of Tongxinluo capsule in preventing and treating restenosis after intracranial and external arterial stenting, and to provide reference for expanding clinical use of traditional Chinese medicine.


Description:

Study participants aged 45-80 years who met the criteria for symptomatic or asymptomatic cerebral artery stenosis and successfully underwent cerebrovascular stenting were randomly divided into test group and control group. On the basis of routine oral treatment ,participants in experimental group were given Tongxinluo capsule. The control group received routine oral treatment. The routine follow-up sites were 1, 3, 6 and 12 months, and clinical data and blood were collected at the initial diagnosis and each follow-up site. SPSS software was used to analyze whether Tongxinluo capsule could reduce restenosis after intracranial and extracranial arterial stenting. During the follow-up, the adverse reactions such as bleeding and gastrointestinal tract were observed.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 200
Est. completion date November 2026
Est. primary completion date November 2025
Accepts healthy volunteers No
Gender All
Age group 45 Years to 80 Years
Eligibility Inclusion Criteria: - The diagnosis of symptomatic cerebral artery stenosis study participants met the above diagnostic criteria; Participants in the study with asymptomatic cerebral artery stenosis or asymptomatic cerebral artery stenosis met the indications for stent implantation in the Chinese Guidelines for Intravascular Interventional Treatment of Ischemic Cerebrovascular Diseases 2015, and successfully underwent cerebrovascular stenting (residual stenosis after vascular opening =30% after stent implantation). - I am 45-80 years old and I and my family members agree to participate in this study. - It can tolerate statin and platelet therapy without serious complications. Exclusion Criteria: - Patients with other intracranial lesions; - Recent bleeding history or bleeding tendency; - Patients with severe cardiac, liver and renal insufficiency, hypertension and diabetes were not well controlled; (4) Severe symptoms of stroke or neurological impairment and unstable symptoms after surgery; (5) Severely infected persons who cannot be controlled; ? Patients who stop taking medicine for more than 2 months for various reasons; ? Taking proprietary Chinese medicine or traditional Chinese medicine with similar efficacy.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Tongxinluo capsule
On the basis of conventional treatment, the study participants in the experimental group were given Tongxinluo capsule for 12 months.
Other:
Primary therapy
Routine oral aspirin enteric-coated tablets, clopidogrel bisulfate tablets and rosuvastatin calcium tablets (or atorvastatin calcium tablets)

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Yanbin Li

Outcome

Type Measure Description Time frame Safety issue
Primary Changes of vascular stenosis rate after intracranial and extracranial arterial stenting According to NASCET experimental measurement standards, stenosis rate = (normal vascular lumen diameter - residual diameter at stenosis)/normal vascular lumen diameter *100%. Comparison of CTA or DSA to evaluate the change of vascular stenosis rate after intracranial and extracranial arterial stenting; The incidence of cerebral ischemic events and intracranial hemorrhage events (responsible vessels and non-responsible vessels) were assessed by MR. Blood routine, liver and kidney function, blood lipids and hsCRP were recorded. The incidence and mortality of symptomatic intracranial hemorrhage were analyzed. Adverse events (e.g. abdominal pain, diarrhea, nausea, vomiting, bleeding, etc.) The 12th month
See also
  Status Clinical Trial Phase
Completed NCT05591365 - Exercise Training in Coronary Artery Disease Patients After Stenting N/A
Completed NCT05315193 - Effect of Exercise Training in Coronary Artery Disease Patients After Stenting N/A
Active, not recruiting NCT03097679 - Self-expanding Nitinol Stents of High vs. Low Chronic Outward Force in De-novo Femoropopliteal Occlusive Arterial Lesions N/A
Recruiting NCT05346068 - The Value of IVL Compared To OPN Non-Compliant Balloons for Treatment of RefractorY Coronary Lesions (VICTORY) Trial N/A
Active, not recruiting NCT03349385 - Registry of Secondary Revascularization
Recruiting NCT04325867 - Integrated Distance Management Strategy for Patients With Cardiovascular Diseases in the Context of COVID-19 N/A
Recruiting NCT05244629 - Copenhagen Mesenteric Stent Study - A Randomized Trial of Stent Versus Covered Stent Treatment for Chronic Mesenteric Ischemia N/A
Completed NCT03544294 - veRy Thin Stents for Patients With Left mAIn or bifurcatioN in Real Life: the RAIN a Multicenter Study
Completed NCT05217459 - The Efficacy and Safety of Intracranial Self-expanding DES in Symptomatic Intracranial Atherosclerotic Disease N/A
Recruiting NCT05205148 - Ultrathin DES in Complex PCI Scenarios: the ULTRA a Multicenter Study
Not yet recruiting NCT03375528 - Matrix Metalloproteinases Expression in the Neointimal Hyperplasia Induced by Drug Eluting Stent (DES) Implantation N/A
Completed NCT06276114 - IVL vs ELCA for Stent Underexpantsion (IVL-ELCA DRAGON)